Pharmaceuticals

In a Form 4 filed earlier today, Bristol-Myers Squibb Co. (NYSE: BMY) Officer, Notaristefani De, reported that he sold 10,000 shares of BMY on December 17th for an average price of $26.45. The transaction totaled $264,500. Mr. De owns 60,652 direct shares and 834 indirect shares of BMY. Source:...

Genzyme Corporation (NASDAQ: GENZ) held an analyst and investor day today to discuss the market potential of alemtuzumab for multiple sclerosis at an event for investors and analysts in New York. During the two-hour presentation, the company shared internal market research and independent, third-...

Shares of Jazz Pharmaceuticals (NASDAQ: JAZZ) are higher on the session by 3.34%, currently trading at $19.63. The stock has been moving largely higher over the past six months and is currently trading above the 50-day and 200-day moving averages. Options traders are buying calls on the name today...

French pharma giant Sanofi-Aventis (SNY) recently entered into two agreements in order to bolster its oncology franchise. While the first agreement was signed with Avila Therapeutics, the second was signed with Merck KGaA (MKGAF).  Avila Deal Under the first agreement, which is initially for...

French pharma giant Sanofi-Aventis (SNY) recently entered into two agreements in order to bolster its oncology franchise. While the first agreement was signed with Avila Therapeutics, the second was signed with Merck KGaA (MKGAF).  Avila Deal Under the first agreement, which is initially for...

Few breakout plays that I have my eyes on this morning. Amazon.com (AMZN), in particular, is really enticing. RF Micro Devices (RFMD) and Perrigo (PRGO) have a little ways to go still. But all three of them offer intriguing opportunities.  Here's the breakout charts. Read more...

Most US stocks rose Friday, sending the S&P 500 Index to a two-year high, as better-than-projected earnings forecasts at Oracle Corp. and Research In Motion Ltd. While the takeover of a regional bank overshadowed concern Europe's debt crisis will spread. Oracle (NASDAQ: ORCL) jumped 3.9...

VIVUS, Inc. (NASDAQ: VVUS) is slightly higher this morning, gaining 0.4% after the company filed a European Marketing Authorization application for QNEXA in the treatment of obesity. Vivus will market its Vivus drug if it is approved by the European Medicines Agency (EMA), which is similar to our...

The Gruenenthal Group and Forest Laboratories, Inc. (NYSE: FRX), today announced that Forest Healthcare B.V., a wholly owned subsidiary of Forest Laboratories, Inc. and Gruenenthal GmbH, have entered into an agreement whereby Forest has acquired all rights currently held by Gruenenthal for colistin...

Astrazeneca (NYSE: AZN) is down 0.5% in pre-market trading, after it said on Friday that there would be a further delay to its Brilinta heart drug after the U.S. Food and Drug Administration asked for extra analysis. It's the second time this year the potential blockbuster product has been delayed.

Magic Software Enterprises Ltd (NASDAQ: MGIC) dipped 1.70% to $7.50 in the pre-market session. MGIC's trailing-twelve-month ROA is 5.71%. Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA) lost 0.83% to $51.50 in the pre-market session. TEVA's trailing-twelve-month ROE is 14.36%. Marvell Technology...

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) today announced that Philip W. Loberg, Valeant's former senior vice president and corporate controller, has been named to the role of interim chief financial officer, effective immediately, replacing Peggy Mulligan, former chief financial...

Incyte Corporation (NASDAQ: INCY) rose 17.98% to $17.72 in the pre-market session. INCY's shares have surged 76.91% over the past 52 weeks, while the S&P 500 index has gained 12.83% in the same period. Applied Signal Technology Inc (NASDAQ: APSG) added 7.94% to $37.80 in the pre-market session...

Bristol-Myers Squibb Company (NYSE: BMY) and Oncolys BioPharma Inc. announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire exclusive worldwide rights to manufacture, develop and commercialize festinavir, a once-a-day, orally available...

CoreSite Realty Corporation (NYSE: COR) today announced that its Board declared a dividend of $0.13 per share of common stock and common stock equivalents for the fourth quarter of 2010.